TP040/#1418 Palbociclib plus letrozole combination after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube or peritoneal cancer (LACOG 1018)

Fernanda Damian,Taiane Rebelatto,Andreia Cristina De Melo,Gustavo Werutsky,Aknar De Carvalho Calabrich,Graziela Zibetti Dal Molin,Rafaela De Jesus,Elias Abdo Filho,Mirela Foresti Jimenez,Angelica Rodrigues

doi:10.1136/ijgc-2022-igcs.549

TP040/#1418 Palbociclib plus letrozole combination after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube or peritoneal cancer (LACOG 1018)

Fernanda Damian, Taiane Rebelatto + Show 8 more

Open Access

https://doi.org/10.1136/ijgc-2022-igcs.549

Copy DOI

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Publication Date: Dec 1, 2022

Affiliation: Hospital São Lucas da PUCRS, Eastern Cooperative Oncology Group, Beneficência Portuguesa de São Paulo, Instituto do Câncer do Estado de São Paulo

#Ovarian High-grade Serous Carcinoma #Days In 28-day Cycles + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

ObjectivesLimited treatment options are available for patients with ovarian high-grade serous carcinoma (HGSC) or endometrioid carcinoma (EC) who progress after receiving chemotherapy for locoregional recurrence or metastatic disease. About 38–60%...

Full Text